Diego Miralles

Adaptive Biotechnologies, the leader in next generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, announced the appointment of Diego Miralles, M.D., as President of Adaptive Therapeutics on March 15th.

Most recently Dr. Miralles was Global Head at Johnson & Johnson Innovation where he established the Johnson & Johnson Innovation Centers, JLABS, and Janssen Healthcare Innovation. Dr. Miralles will build the Therapeutics Division of Adaptive, and head the Company’s efforts to leverage its best-in-class platform for identifying T- and B-cell receptors for use in therapies that will directly impact patient outcomes. In addition, Dr. Miralles will provide both scientific and commercial guidance to the existing and future programs and partnerships that Adaptive is implementing.

“Adaptive’s ground-breaking technology has created a substantial opportunity in the broad immune-based therapeutics space,” said Dr. Miralles. “I am passionate about the potential to positively impact patient outcomes and I am excited about the biological possibilities that such a technology enables. I see this as a great chance to make a difference to patients with currently unaddressed medical needs.”

Adaptive Therapeutics is a new division of Adaptive Biotechnologies focused on the application of the Company’s proprietary technologies to pair T- and B-cell receptor chains together at high throughout and to determine the antigen-specificity of these receptors for therapeutic discovery. Adaptive is exploring many potential therapeutic applications including adoptive cell therapy, passive immunization, novel target discovery, and antibody engineering.